Guardant Health, Inc. (GH)

19.44 +0.80 (+4.29%) 收市：04:00PM EDT

Guardant Health, Inc.

3100 Hanover Street
Palo Alto, CA 94304
United States
855 698 8887
https://guardanthealth.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 1,768

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Helmy Eltoukhy Ph.D.	Co-Founder, Co-CEO & Chairman	11.59k	無	1980
Dr. AmirAli Talasaz Ph.D.	Co-CEO & Director	26.41k	無	1980
Mr. Michael Bell	Chief Financial Officer	819.27k	無	1969
Ms. Darya Chudova	Chief Technology Officer	715.66k	無	1974
Dr. Craig Eagle M.D.	Chief Medical Officer	844.86k	無	1967
Mr. Christopher Freeman	Chief Commercial Officer	826.27k	無	1974
Mr. Kumud Kalia	Chief Information Officer	無	無	1966
Mr. John G. Saia	Chief Legal Officer & Corporate Secretary	627.18k	無	1973
Ms. Jennifer Higgins	Senior Vice President of Public Affairs	無	無	無
Ms. Terilyn Juarez Monroe	Chief People Officer	無	無	1967

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

公司管治

截至 2024年5月1日 止，Guardant Health, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：1；董事會：7；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。